Luca Agnelli
Overview
Explore the profile of Luca Agnelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
99
Citations
2528
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bozzi F, Conca E, Silvestri M, Dagrada G, Ardore A, Penso D, et al.
Sci Rep
. 2025 Feb;
15(1):4314.
PMID: 39910096
Copy number alterations (CNAs) play a fundamental role in cancer development and constitute a potential tool for tailored treatments. The CNAs recognition in formalin fixed paraffin embedded (FFPE) material for...
2.
Calin G, Hube F, Ladomery M, Delihas N, Ferracin M, Poliseno L, et al.
Noncoding RNA
. 2024 Dec;
10(6.
PMID: 39728607
The Journal Editorial Board Members would like to congratulate Victor Ambros and Gary Ruvkun, who were jointly awarded the 2024 Nobel Prize in Physiology or Medicine for their groundbreaking discovery...
3.
Ligorio F, Vingiani A, Torelli T, Sposetti C, Drufuca L, Iannelli F, et al.
Cell Metab
. 2024 Dec;
37(2):330-344.e7.
PMID: 39694040
In preclinical experiments, cyclic fasting-mimicking diets (FMDs) showed broad anticancer effects in combination with chemotherapy. Among different tumor types, triple-negative breast cancer (TNBC) is exquisitely sensitive to FMD. However, the...
4.
Nichetti F, Silvestri M, Agnelli L, Franza A, Pircher C, Rota S, et al.
Cancer Med
. 2024 Dec;
13(23):e70393.
PMID: 39618336
Background: The identification of actionable molecular targets of pancreatic cancer (PAC) is key to improving patient outcomes. We hypothesized O6-methylguanine-DNA methyltransferase (MGMT) silencing may occur in a subset of PAC...
5.
Azzollini J, Capone I, Duca M, Vingiani A, Piccolo A, Agnelli L, et al.
Tumori
. 2024 Sep;
:3008916241280127.
PMID: 39311051
Introduction: Tumour /2 sequencing has progressively increased along with the expanding indications for poly(ADP-ribose) polymerase inhibitors. In our study, we investigated the feasibility and outcomes of a workflow for the...
6.
Agnelli L, Villa A, Butt F, Duca M, Guidi A, Carapezza M, et al.
Tumori
. 2024 Apr;
110(5):304-308.
PMID: 38676437
The use of Digital Healthcare Products is leading to significant improvements in clinical practice. Herein, we discuss the development of PROACT 2.0 (Patient Reported Opinions About Clinical Tolerability v2.0), a...
7.
Carniti C, Caldarelli N, Agnelli L, Torelli T, Ljevar S, Jonnalagadda S, et al.
Blood Adv
. 2024 Feb;
8(8):1968-1980.
PMID: 38359407
CD19-directed chimeric antigen receptor (CAR) T cells can induce durable remissions in relapsed/refractory large B-cell lymphomas (R/R LBCLs), but 60% of patients do not respond or relapse. Biological mechanisms explaining...
8.
Prelaj A, Ganzinelli M, Provenzano L, Mazzeo L, Viscardi G, Metro G, et al.
Clin Lung Cancer
. 2024 Jan;
25(2):190-195.
PMID: 38262770
Introduction: Despite several therapeutic efforts, lung cancer remains a highly lethal disease. Novel therapeutic approaches encompass immune-checkpoint inhibitors, targeted therapeutics and antibody-drug conjugates, with different results. Several studies have been...
9.
Randon G, Nakamura Y, Yaeger R, Lonardi S, Cremolini C, Elez E, et al.
Clin Cancer Res
. 2023 Aug;
30(2):436-443.
PMID: 37610454
Purpose: To demonstrate the negative prognostic impact of a panel of genomic alterations (PRESSING-HER2 panel) and lack of HER2 amplification by next-generation sequencing (NGS) in patients with HER2+, RAS wild-type...
10.
Garcia J, Storti P, Iannozzi N, Marchica V, Agnelli L, Toscani D, et al.
Haematologica
. 2023 Aug;
109(2):627-631.
PMID: 37608776
No abstract available.